Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Hepatitis C

Free Subscription Articles published in Am J Gastroenterol Retrieve available abstracts of 36 articles: HTML format Text format

Single Articles

June 2018
1. KRAWCZYK M, Gaweda B, Kosnik A, Rejowski S, et al
   Successful DAA-Based Treatment of Hcv-Related Fibrosing Cholestatic Hepatitis After Liver Transplantation Due to a Fulminant Liver Failure.
   Am J Gastroenterol. 2018 Jun 21. pii: 10.1038/s41395-018-0078.
   PubMed     Text format    
   
   
   April 2018
2. ZAMOR PJ, Vierling J, Ghalib R, Luketic V, et al
   Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
   Am J Gastroenterol. 2018 Apr 26. pii: 10.1038/s41395-018-0053.
   PubMed     Text format     Abstract available
   
   
   
3. PERRELLA A, Rinaldi L, Galeota-Lanza A, Izzi A, et al
   DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist.
   Am J Gastroenterol. 2018 Apr 24. pii: 10.1038/s41395-018-0062.
   PubMed     Text format    
   
   
   March 2018
4. WONG RJ, Jain MK, Therapondos G, Shiffman ML, et al
   Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
   Am J Gastroenterol. 2018 Mar 9. pii: 10.1038/s41395-018-0033.
   PubMed     Text format     Abstract available
   
   
   December 2017
5. BUNCHORNTAVAKUL C, Reddy KR
   HCV Therapy in Decompensated Cirrhosis before or after Liver Transplantation: A Paradoxical Quandary.
   Am J Gastroenterol. 2017 Dec 5. pii: ajg2017435. doi: 10.1038/ajg.2017.
   PubMed     Text format    
   
   
   
6. NGUYEN MH, Trinh H, Do S, Nguyen T, et al
   Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naive or Experienced Patients.
   Am J Gastroenterol. 2017;112:1824-1831.
   PubMed     Text format     Abstract available
   
   
   November 2017
7. KWO PY, Shiffman ML, Bernstein DE
   The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.
   Am J Gastroenterol. 2017 Nov 14. doi: 10.1038/ajg.2017.
   PubMed     Text format    
   
   
   
8. SOLLIMA S, Milazzo L, Antinori S, Galli M, et al
   Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV Eradication.
   Am J Gastroenterol. 2017;112:1753-1754.
   PubMed     Text format    
   
   
   
9. LIU X, Shen JJ, Lee JL, Yoo JW, et al
   Cost-Effective but Unaffordable and Unequal Hepatitis C Treatment in the US.
   Am J Gastroenterol. 2017;112:1749.
   PubMed     Text format    
   
   
   
10. FUKUI N, Golabi P, Otgonsuren M, Mishra A, et al
    Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States.
    Am J Gastroenterol. 2017;112:1700-1708.
    PubMed     Text format     Abstract available
    
    
    October 2017
11. WU T, Kwok RM, Tran TT
    Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.
    Am J Gastroenterol. 2017 Oct 31. doi: 10.1038/ajg.2017.
    PubMed     Text format     Abstract available
    
    
    
12. KECK C, Shetty A, Mischen B, Willner I, et al
    Hepatic Splenosis Masquerading as Hepatocellular Carcinoma in a Chronic Hepatitis C Patient.
    Am J Gastroenterol. 2017;112:1493.
    PubMed     Text format    
    
    
    September 2017
13. KOFF RS
    Editorial: Direct Antiviral Agents Eliminate the Age Barrier to Treatment of Chronic Hepatitis C.
    Am J Gastroenterol. 2017;112:1410-1411.
    PubMed     Text format     Abstract available
    
    
    
14. LENS S, Fernandez I, Rodriguez-Tajes S, Hontangas V, et al
    Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
    Am J Gastroenterol. 2017;112:1400-1409.
    PubMed     Text format     Abstract available
    
    
    August 2017
15. MARTIN P, Fabrizi F
    Editorial: Benefit of Direct-Acting Antiviral Therapy For Cryoglobulinemia due to Hepatitis C Infection.
    Am J Gastroenterol. 2017;112:1309-1310.
    PubMed     Text format     Abstract available
    
    
    
16. EMERY JS, Kuczynski M, La D, Almarzooqi S, et al
    Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Am J Gastroenterol. 2017;112:1298-1308.
    PubMed     Text format     Abstract available
    
    
    April 2017
17. LEE MH, Hsiao TI, Subramaniam SR, Le AK, et al
    HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis.
    Am J Gastroenterol. 2017 Apr 25. doi: 10.1038/ajg.2017.
    PubMed     Text format     Abstract available
    
    
    
18. OOKA K, Connolly JJ, Lim JK
    Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.
    Am J Gastroenterol. 2017 Apr 4. doi: 10.1038/ajg.2017.
    PubMed     Text format    
    
    
    February 2017
19. TAKYAR V, Kleiner DE, Koh C
    A Wolf in Sheep's Clothing in the Era of Non-Invasive Staging: Non-Hodgkin's Lymphoma Masquerading as Serologic HCV Cirrhosis.
    Am J Gastroenterol. 2017;112:398-399.
    PubMed     Text format    
    
    
    
20. YANG JD, Mohamed HA, Cvinar JL, Gores GJ, et al
    Corrigendum: Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
    Am J Gastroenterol. 2017;112:402.
    PubMed     Text format    
    
    
    December 2016
21. PILLAI AA, Anania FA, Pearlman BL
    Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.
    Am J Gastroenterol. 2016;111:1854-1856.
    PubMed     Text format    
    
    
    August 2016
22. YANG JD, Mohamed HA, Cvinar JL, Gores GJ, et al
    Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
    Am J Gastroenterol. 2016 Aug 16. doi: 10.1038/ajg.2016.
    PubMed     Text format     Abstract available
    
    
    
23. TROJAN J, Sarrazin C
    Complete Response of Hepatocellular Carcinoma in a Patient With End-stage Liver Disease treated With Nivolumab: Whishful thinking or Possible?
    Am J Gastroenterol. 2016;111:1208-9.
    PubMed     Text format    
    
    
    July 2016
24. SHIFFMAN ML, Rustgi V, Bennett M, Forns X, et al
    Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
    Am J Gastroenterol. 2016;111:1077.
    PubMed     Text format    
    
    
    
25. DI COSTANZO GG, Marino Marsilia G, Tortora R, Di Costanzo G, et al
    Hepatocellular Carcinoma With Peliosis-Like Change-Mimicking Hemangioma: A LI-RADS Exception.
    Am J Gastroenterol. 2016;111:1038-40.
    PubMed     Text format    
    
    
    June 2016
26. SCHITZ A, Moser S, Marchart K, Haltmayer H, et al
    Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.
    Am J Gastroenterol. 2016;111:903-5.
    PubMed     Text format    
    
    
    May 2016
27. STERN R, Hametner S, Ramona AZ, Moser S, et al
    Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
    Am J Gastroenterol. 2016;111:744-5.
    PubMed     Text format    
    
    
    April 2016
28. SHIFFMAN ML, Rustgi V, Bennett M, Forns X, et al
    Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
    Am J Gastroenterol. 2016 Apr 5. doi: 10.1038/ajg.2016.
    PubMed     Text format     Abstract available
    
    
    March 2016
29. YOUNOSSI ZM, Stepanova M, Henry L, Nader F, et al
    An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
    Am J Gastroenterol. 2016 Mar 29. doi: 10.1038/ajg.2016.
    PubMed     Text format     Abstract available
    
    
    
30. SHI Y, Xia F, Li QJ, Li JH, et al
    Magnetic Resonance Elastography for the Evaluation of Liver Fibrosis in Chronic Hepatitis B and C by Using Both Gradient-Recalled Echo and Spin-Echo Echo Planar Imaging: A Prospective Study.
    Am J Gastroenterol. 2016 Mar 15. doi: 10.1038/ajg.2016.
    PubMed     Text format     Abstract available
    
    
    
31. LIU KL, Shih IL, Huang YC, Chen CH, et al
    Image of the Month: Abdominoscrotal Hydrocele.
    Am J Gastroenterol. 2016;111:312.
    PubMed     Text format    
    
    
    February 2016
32. PILLAI AA, Wedd J, Norvell JP, Parekh S, et al
    Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
    Am J Gastroenterol. 2016 Feb 2. doi: 10.1038/ajg.2015.
    PubMed     Text format     Abstract available
    
    
    
33. TRAN TT, Ahn J, Reau NS
    ACG Clinical Guideline: Liver Disease and Pregnancy.
    Am J Gastroenterol. 2016;111:176-94.
    PubMed     Text format     Abstract available
    
    
    November 2015
34. YANG JD, Gyedu A, Afihene MY, Duduyemi BM, et al
    Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B.
    Am J Gastroenterol. 2015;110:1629-31.
    PubMed     Text format    
    
    
    July 2015
35. SHIFFMAN ML, James AM, Long AG, Alexander PC, et al
    Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin.
    Am J Gastroenterol. 2015 Jul 28. doi: 10.1038/ajg.2015.
    PubMed     Text format     Abstract available
    
    
    
36. GORDON SC, Lamerato LE, Rupp LB, Holmberg SD, et al
    Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study.
    Am J Gastroenterol. 2015 Jul 28. doi: 10.1038/ajg.2015.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: